Chemi-Verse™ FYN Kinase Assay Kit
The Chemi-Verse™ FYN Kinase Assay Kit is designed to measure FYN (FYN proto-oncogene, Src family tyrosine kinase) tyrosine kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified FYN, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.
Need us to run inhibitor screens or profile your compounds against FYN? Check out our Kinase Screening Services.
- ADP-Glo™ Kinase Assay (Promega #V6930)
- DTT (Dithiothreitol), 1M, optional
- Microplate reader capable of reading luminescence
- Adjustable micropipettor and sterile tips
- 30°C incubator
| Catalog # | Name | Amount | Storage |
| 40433 | FYN, FLAG-Tag* | 3 µg | -80°C |
| 79334 | 5x Kinase Buffer 1 | 1.5 ml | -20°C |
| 79686 | 500 µM ATP | 50 µl | -20°C |
| 40217 | PTK Substrate Poly(Glu:Tyr 4:1) (10 mg/ml) | 50 µl | -20°C |
| 82545 | White 96-well plate | 1 | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
FYN, also known as p59-FYN, SLK, SYN, is a member of the SFK (Src family of kinase) non-receptor tyrosine kinase protein family. It is involved in cell growth, adhesion and cytoskeletal remodeling, axon guidance and synaptic function, platelet activation and T-cell receptor signaling. Its levels are regulated by miRNA, transcription factors such as STAT5 (signal transducer and activator of transcription 5) and RUNX2 (runt-related transcription factor 2), and the Cbl (Casitas B-lineage lymphoma) ubiquitin E3 ligase. It is normally a tumor suppressor, but dysfunction can lead to prostate cancer, leukemia, pancreatic cancer, breast cancer and others. Downregulation of miR-153-3p levels leads to increased levels of FYN in ESCC (esophageal squamous cell carcinoma). On the other hand, miR-381 downregulates FYN and can make breast cancer cells more susceptible to doxorubicin. FYN activity is regulated by multiple upstream proteins, including CD16 and KRAS (Kirsten rat sarcoma), and in turn can regulate many substrates that are involved in cell growth. This protein is also involved in the development of drug resistance, as in the resistance to imatinib in leukemia. Several inhibitors have been developed to target FYN, with saracatinib being in phase II clinical trials for prostate cancer. Inhibition of FYN is of interest in Alzheimer’s disease (AD), as this protein acts downstream on the pathological pathway of amyloid beta (Aβ) that leads to the disease. Oligomeric Aβ binds to PrPC (cellular prion protein) and activates a pathway dependent on mGluR5 (metabotropic glutamate receptor 5) and FYN. Thus, targeting FYN with saracatinib for the treatment of AD is in clinical trial. These multiple crucial roles make this protein an attractive therapeutic target in cancer and AD.
Nygaard H., 2018 Biol Psychiatry 83(4): 369-376.
Feng S. and Fu Y., 2023 Journal of Translational Medicine 21:84.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.